GSK

(IN BRIEF) GSK licensor Hansoh Pharma has reported positive results from ARTEMIS-011, a pivotal phase III trial of risvutatug rezetecan, or Ris-Rez, in patients in China with relapsed osteosarcoma after at least two prior lines of systemic therapy. The trial … Read the full press release →

(IN BRIEF) GSK has announced that momelotinib, a differentiated JAK inhibitor marketed as Ojjaara or Omjjara in approved indications, has received orphan drug designations from the US Food and Drug Administration and the European Medicines Agency for the treatment of … Read the full press release →

(IN BRIEF) GSK has formed an exclusive partnership with Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group to accelerate the launch of bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, in mainland China. The agreement combines GSK’s drug innovation … Read the full press release →

(IN BRIEF) GSK has announced that China’s National Medical Products Administration has accepted for review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide designed to treat adults with chronic hepatitis B. The submission is supported by Phase III … Read the full press release →

(IN BRIEF) GSK has secured approval in China for Exdensur (depemokimab), a first-of-its-kind ultra-long-acting biologic for treating severe eosinophilic asthma in patients aged 12 and above. Approved by China’s National Medical Products Administration, the therapy offers a novel treatment approach … Read the full press release →

(IN BRIEF) GSK plc has received Orphan Drug Designation in Japan for its investigational antibody-drug conjugate risvutatug rezetecan (Ris-Rez) for the treatment of small-cell lung cancer, supported by early clinical data showing durable responses in patients with extensive-stage disease. SCLC, … Read the full press release →

(IN BRIEF) GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. The therapy is … Read the full press release →

(IN BRIEF) GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary diseases. The acquisition includes HS235, an investigational activin signalling inhibitor … Read the full press release →

(IN BRIEF) GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils who are already receiving inhaled triple therapy, making it the … Read the full press release →